Notice of Amendment to PA-08-127, PA-08-128, and PA-08-129, Prescription Drug Misuse (R01, R03, R21)

Notice Number: NOT-DA-09-011

Key Dates
Release Date:  August 26, 2009

Issued by
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov)

Purpose

This Notice announces a change to PA-08-127, PA-08-128, and PA-08-129, “Prescription Drug Misuse” (R01, R03, R21) (http://grants.nih.gov/grants/guide/pa-files/PA-08-127.html; http://grants.nih.gov/grants/guide/pa-files/PA-08-128.html; http://grants.nih.gov/grants/guide/pa-files/PA-08-129.html). 

Background:  Through this Notice, the National Institute on Drug Abuse (NIDA) and the National Institute on Mental Health (NIMH) encourage investigators to propose research studies which integrate drug abuse research in dental settings, with a particular focus on opioid prescribing in dental settings and its potential link to opioid diversion and misuse among the general population and among adolescents in particular.  Over the past several years, national data has suggested a substantial rise in the number of youth who are abusing prescription medications, especially opioids.  Some exploratory data analyses have suggested that dentists are among the top prescribers of opioids to adolescents; this is likely due to the common procedure among adolescents of third molar extraction, subsequent to which a brief, time-limited prescription of an opioid analgesic is often prescribed.  Broadly, this announcement is meant to foster further research into opioid prescribing practices in dental settings and the potential relationship to misuse/abuse of opioid medications.      

Eligible Applications:  Examples of the types of research include, but are not limited to: 

  • Further research on standard practices for dentists for prescribing opioid analgesics, perception of risk and safety of opioid analgesics among dentists, and awareness among dental practitioners regarding the growing problem of prescription drug misuse/abuse.
  • Research on opioid misuse/abuse among adolescents, to include evaluation of sources of opioids from dental and other clinical settings.
  • Research on prevention practices for curbing diversion of prescriptions opioids, to include potential prevention practices in dental settings.
  • Research among dental patients regarding opioid diversion practices and behaviors/motivations of persons who misuse/abuse opioids.

Mechanism of Support: This change applies to the following Funding Opportunity Announcements:   R01, R03, and R21 applications:

PA-08-127 (http://grants.nih.gov/grants/guide/pa-files/PA-08-127.html);
PA-08-128 (http://grants.nih.gov/grants/guide/pa-files/PA-08-128.html); 
PA-08-129 (http://grants.nih.gov/grants/guide/pa-files/PA-08-129.html). 

Other than the change described above, all other aspects of these FOAs remain unchanged.

Inquiries

Inquiries regarding this Notice should be directed to:

Aria Davis Crump, Sc.D.
National Institute on Drug Abuse
National Institutes of Health
US Department of Health and Human Services
6001 Executive Boulevard, Room 5153, MSC 9589
Bethesda, MD 20892-9589
Email: [email protected]
Telephone: 301-443-6504
Fax: 301-443-2636

Jeffrey D. Schulden, MD
National Institute on Drug Abuse
National Institutes of Health
US Department of Health and Human Services
6001 Executive Boulevard, Room 5153, MSC 9589
Bethesda, MD 20892-9589
Email: [email protected]
Telephone: (301) 402-1526
Fax: 301-443-2636

National Institute of Mental Health:

Mi Hillefors, M.D., Ph.D.
Chief, Psychotic Disorders Treatment Development Program &
Mood and Anxiety Disorders Treatment Development Program
Experimental Therapeutics Branch
Division of Adult Translational Research and Treatment Development
National Institute of Mental Health
National Institutes of Health
6001 Executive Blvd., Room 7125 MSC 9632
Bethesda, MD 20892-9632
Rockville, MD 20852 (Visitors, FedEx, UPS, etc.)
Telephone: 301-443-1692
Fax: 301-443-1425
E-mail: [email protected]

NIDA Financial/Grants Management Contact:

Edith Davis
Grants Management Branch
National Institute on Drug Abuse/NIH/DHSS
6101 Executive Boulevard, Room 260
Bethesda, MD 20892-8403
Telephone: 301-443-6710
Fax: 301-594-6849
Email: [email protected]